☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search
Search here
Search here
Subscribe Now
Cheplapharm
Takeda Divests its Select Non-Core Assets in the EU and Canada to Cheplapharm for $562M
September 9, 2020
AstraZeneca to Divest Worldwide Commercialization Rights of Losec (omeprazole) to Cheplapharm
October 1, 2019
Load more...
Back to Home
Modal title
×
Modal body text goes here.
